Toxys Opens US Office and Production Facility to Accelerate Growth

Toxys Opens US Office and Production Facility to Accelerate Growth

OEGSTGEEST, the Netherlands, March 16, 2022 / B3C newswire / -- Toxys BV, a Dutch biotech company that offers a broad spectrum of innovative in vitro toxicology solutions for the safety assessment of novel medicines, (agro)chemicals, cosmetics, and food ingredients, today announces the opening of a sales office in New York (NY) and a production facility in Gaithersburg (DE) to accelerate the company’s growth. With these new facilities, Toxys will be able to better serve its clients in North America and make the Toxys assays readily available.

The opening of an office and production facility in the US supports the company’s growth strategy to become the global leading supplier of expert mechanistic in vitro chemical safety assays. These assays provide animal-free safety testing of novel medicines, chemicals, and consumer products. Toxys is a recognized expert in the fields of genotoxicity, developmental toxicology, and mechanistic toxicity testing and has developed the unique ToxTracker®, ReproTracker® and ToxProfiler™ assays.

“The decision to expand our presence into the United States was a logical step in our business growth strategy,” said Giel Hendriks, president. “We have made important progress on development of innovative animal-free tests for drug and chemical safety testing. With our new US facilities, we are ready to further expand our business globally and continue to work on the development of novel solutions for toxicological research”.